Allergan: raises FY sales targets
(CercleFinance.com) - As it unveiled its quarterly results, Allergan confirms that it is now looking for non-GAAP EPS of over 16.
55 dollars and that it now expects income of between 15.4 billion and 15.6 billion dollars (vs. 15.1 billion to 15.4 billion dollars previously).
In Q2 2019, the Ireland-based pharmaceutical company recorded adjusted EPS that is down 0.9% at 4.38 dollars, four cents above the consensus.
At 4.09 billion dollars, its revenue fell 0.8% as reported, although increased by 1.2% excluding FX factors, with the strength of key products such as Botox, Vraylar and Juvéderm.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
55 dollars and that it now expects income of between 15.4 billion and 15.6 billion dollars (vs. 15.1 billion to 15.4 billion dollars previously).
In Q2 2019, the Ireland-based pharmaceutical company recorded adjusted EPS that is down 0.9% at 4.38 dollars, four cents above the consensus.
At 4.09 billion dollars, its revenue fell 0.8% as reported, although increased by 1.2% excluding FX factors, with the strength of key products such as Botox, Vraylar and Juvéderm.
Copyright (c) 2019 CercleFinance.com. All rights reserved.